이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Biomarkers and Pharmacogenomics for Precision Depression Therapy

Study on Multidimensional Biomarkers of Depression and Individualized Therapy Based on Pharmacogenomic Technology

Background: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50% response rate.

Objective and Design: This prospective, randomized, parallel-controlled trial aims to enroll 220 MDD patients, who will be allocated 1:1 to either a pharmacogenomics (PGx)-guided therapy group (treatment selection based on genetic testing) or a conventional treatment group (treatment as usual per guidelines), with a 12-week follow-up. Additionally, a matched healthy control cohort will be included for cross-sectional biomarker comparisons.

Intervention and Outcomes: Patients in the PGx group undergo buccal swab testing for key genetic polymorphisms (e.g., CYP2D6, CYP2C19) to inform antidepressant type and dosage. The primary outcome is the 12-week response rate (≥50% reduction in HAMD-17 score from baseline). Secondary outcomes include remission rate, incidence of adverse drug reactions, and medication adjustment frequency.

Exploratory Aims: Multidimensional baseline data-including resting-state fMRI (VMHC), peripheral blood biomarkers (inflammatory cytokines, thyroid function, BDNF), urinary metabolites, and gut microbiome-will be integrated to construct a predictive model for treatment efficacy and to identify novel MDD biomarkers.

Scientific Significance: This study seeks to validate the clinical utility of PGx-guided prescribing and to advance the shift from symptom-based diagnosis towards a biological-characteristic-based precision medicine framework for depression.

연구 개요

상세 설명

  1. Study Design and Overall Framework This is a prospective, randomized, parallel-controlled, single-center clinical trial, conducted in accordance with the Declaration of Helsinki and Chinese ethical regulations. A total of 220 patients diagnosed with major depressive disorder (MDD) per DSM-5 criteria will be enrolled, along with 80-100 age-, sex-, and education-matched healthy controls (retrospective data from an anonymized health check-up database). Patient participants will be randomized 1:1 via block randomization (block size 4-6) into: (1) Pharmacogenomics (PGx)-guided therapy group; (2) Conventional treatment group (guideline- and experience-based). The follow-up duration is 12 weeks, with assessments scheduled at baseline, Week 4, Week 8, and Week 12 (endpoint). Healthy controls provide only cross-sectional baseline data.
  2. Participant Eligibility and Screening Inclusion criteria for patients: (1) MDD diagnosis confirmed by two senior psychiatrists; (2) HAMD-17 total score ≥17 at baseline; (3) aged 14-60 years; (4) at least junior high school education. Exclusion criteria include: other psychiatric disorders, organic CNS diseases, severe physical illnesses, substance abuse history, physical therapy within the past year, pregnancy/lactation, or significant abnormalities in ECG, routine blood tests, liver/kidney/thyroid function. Written informed consent is obtained from all patients (and legal guardians for minors or cognitively impaired individuals).
  3. Interventions and Procedures (1) PGx-guided group: Buccal swab samples are collected at baseline for targeted genotyping (chip or sequencing) of key polymorphisms in drug-metabolizing enzymes, transporters, and targets, including CYP2D6, CYP2C19, CYP3A4/5, CYP1A2, CYP2B6, CYP2C9, HTR2A, and SLC6A4. The report classifies patients into ultrarapid, normal, intermediate, or poor metabolizer phenotypes and provides prescribing recommendations for SSRIs (escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, citalopram), SNRIs (venlafaxine, duloxetine, milnacipran), NaSSAs (mirtazapine), and others (bupropion). Clinicians prioritize drugs predicted to offer better efficacy and lower risk, adjusting starting doses based on metabolic type.

(2) Conventional group: Buccal swabs are collected but not analyzed (sham procedure to maintain blinding balance). Clinicians prescribe antidepressants following Chinese depression treatment guidelines, based on symptom profiles, prior medication history, and clinical judgment. Both groups allow dose adjustments during follow-up, with all changes documented.

4. Data Acquisition and Multi-Dimensional Biomarker Assessment All participants (including healthy controls) undergo baseline assessments: (1) Demographics and clinical history; (2) Peripheral blood for inflammatory markers (CRP, IL-6), endocrine function (thyroid panel: TSH, FT3, FT4), neurotrophic factor (BDNF), and routine biochemistry (liver/kidney function, glucose, lipids); (3) Urine and stool samples for future metabolomic and gut microbiome analyses; (4) Resting-state fMRI scanning, with primary extraction of voxel-mirrored homotopic connectivity (VMHC), and optional exploration of ALFF and FCD; (5) Scale assessments: HAMD-17, HAMA, and TESS. Follow-up visits (Weeks 4, 8, 12) for patient groups include only scale assessments and adverse event recording, without repeated blood draws or imaging.

5. Outcome Definitions Primary outcome: 12-week response rate, defined as the proportion of patients with ≥50% reduction in HAMD-17 total score from baseline (χ² test between groups).

Secondary outcomes: (1) 12-week remission rate (HAMD-17 ≤7); (2) Trajectory of depressive symptoms across time points (repeated-measures ANOVA); (3) Incidence of treatment-emergent adverse events (TESS); (4) Dropout rate due to adverse events; (5) Concordance between initial drug choice and PGx recommendations (descriptive, intervention group only); (6) Time to reach stable effective dose (survival analysis); (7) Frequency of medication adjustments (Mann-Whitney U test).

Exploratory outcomes: (1) Efficacy differences across distinct metabolic phenotypes; (2) Correlations of baseline VMHC and blood biomarkers with 12-week efficacy; (3) Case-control comparisons of all biomarker dimensions; (4) Construction of a comprehensive predictive model integrating clinical, imaging, blood, and genomic features using multivariate logistic regression or machine learning (e.g., random forest, SVM), with cross-validation for performance evaluation (AUC, sensitivity, specificity).

6. Sample Size Justification Sample size is calculated for the primary outcome (two independent proportions, χ² test) using PASS 15.0. Parameters: α=0.05 (two-sided), power 1-β=0.80. Based on published literature, the 12-week response rate for conventional treatment is estimated at 50% (P₁), and the PGx-guided group is expected to achieve 70% (P₂), an absolute difference of 20%. The required sample size is 86 per group. Accounting for a 20% dropout rate, the adjusted sample size is 107.5 per group, rounded up to 110 per group, yielding a total of 220 patients to ensure adequate statistical power.

7. Statistical Analysis Plan Analyses will be performed using SPSS 26.0 and R 4.0. Efficacy analysis follows the intention-to-treat (ITT) principle with multiple imputation for missing data; per-protocol analysis serves as a sensitivity check. Baseline comparisons use t-tests or Mann-Whitney U tests for continuous variables and χ² or Fisher's exact tests for categorical variables. Repeated measures are analyzed using mixed-effects models or repeated-measures ANOVA, adjusting for baseline values. Biomarker exploration: Case-control comparisons use ANCOVA (adjusting for age, sex, etc.); correlation analyses use Pearson/Spearman coefficients. Predictive modeling: Candidate variables with P<0.10 in univariate analysis enter multivariate logistic regression (forward stepwise) or machine learning algorithms. Internal validation employs 5-fold cross-validation, with AUC assessing discrimination and calibration curves assessing goodness-of-fit.

8. Data Management and Quality Control Data are recorded in an electronic data capture (EDC) system with double-entry verification. Biological samples are aliquoted, coded, and stored at -80°C with routine quality checks. MRI data are processed independently by two blinded neuroradiologists. All adverse events are assessed for severity and causality by study physicians and reported to the ethics committee. Independent monitoring audits are conducted periodically.

9. Ethical Approval and Informed Consent This study has been approved by the Ethics Committee of the Fourth Affiliated Hospital of Zhejiang University School of Medicine. Written informed consent is obtained from all patient participants (or their legal guardians) prior to any study procedures. For healthy controls, data are derived from an anonymized health check-up database archived before January 31, 2026; original consent covered research use, and the ethics committee granted a waiver of re-consent.

10. Study Timeline The total study duration is 36 months from ethics approval: 6 months for preparation and training, 24 months for enrollment and 12-week follow-up completion, and 6 months for data cleaning, statistical analysis, and final reporting.

연구 유형

중재적

등록 (추정된)

220

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  1. Clinical diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria
  2. Age between 18 and 60 years
  3. Baseline HAMD-17 total score ≥ 17
  4. Ability to provide written informed consent

Exclusion Criteria:

  1. History of other psychiatric disorders (e.g., bipolar disorder, schizophrenia)
  2. Presence of severe physical illnesses or major central nervous system diseases
  3. History of sedative-hypnotic, alcohol, or substance abuse
  4. Pregnancy, lactation, or planning to become pregnant during the study
  5. Significant abnormalities in ECG, complete blood count, or liver/kidney/thyroid function tests

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Pharmacogenomics-Guided Antidepressant Therapy
Patients receive pharmacogenomic testing via buccal swab at baseline. The test detects polymorphisms in CYP2D6, CYP2C19, CYP3A4/5, CYP1A2, CYP2B6, CYP2C9, HTR2A, and SLC6A4. Clinicians select antidepressant type and starting dosage based on the genotype report (metabolizer phenotype) to optimize efficacy and minimize adverse drug reactions.
Buccal swab collection for targeted genotyping of polymorphisms in CYP2D6, CYP2C19, CYP3A4/5, CYP1A2, CYP2B6, CYP2C9, HTR2A, and SLC6A4. The assay classifies patients into ultrarapid, normal, intermediate, or poor metabolizer phenotypes for CYP450 enzymes, and provides response/risk predictions for SSRIs (escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, citalopram), SNRIs (venlafaxine, duloxetine, milnacipran), mirtazapine, and bupropion. A written report with genotype-based drug and dosage recommendations is issued to the clinician.
다른 이름들:
  • PGx Genotyping
  • CYP450 Genotyping Panel
  • Antidepressant Genetic Test
활성 비교기: Guideline-Based Conventional Antidepressant Therapy
Patients undergo a sham buccal swab procedure without genetic analysis. Clinicians prescribe antidepressants following the Chinese Depression Prevention and Treatment Guidelines, based on clinical experience, symptom profiles, prior medication history, and physical condition. Medication adjustments are allowed during the 12-week follow-up.
Oral administration of first-line or second-line antidepressants approved for major depressive disorder, including selective serotonin reuptake inhibitors (SSRIs: escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, citalopram), serotonin-norepinephrine reuptake inhibitors (SNRIs: venlafaxine, duloxetine, milnacipran), noradrenergic and specific serotonergic antidepressants (NaSSA: mirtazapine), and bupropion. Dosing follows clinical guidelines. In the experimental arm, selection and initial dosage are guided by the pharmacogenomic test report; in the conventional arm, selection and dosage are determined by physician expertise and standard care guidelines. Dose adjustments are permitted at Weeks 4, 8, and 12 based on efficacy and tolerability.
다른 이름들:
  • 부프로피온
  • 미르타자핀
  • SSRIs
  • SNRIs

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Title: 12-Week Response Rate Defined by HAMD-17 Score Reduction
기간: From baseline to Week 12.
Unit: percent. The proportion of participants achieving a clinical response, defined as a reduction in HAMD-17 score of 50% or greater from baseline.
From baseline to Week 12.

2차 결과 측정

결과 측정
측정값 설명
기간
12-Week Remission Rate Defined by HAMD-17 Total Score
기간: Week 12.
Unit: percent. The proportion of participants achieving remission, defined as a HAMD-17 total score of 7 or less. Assessments are conducted by trained psychiatrists blinded to group allocation.
Week 12.
Longitudinal Trajectory of Depressive Symptoms Assessed by HAMD-17 Over 12 Weeks
기간: Baseline, Week 4, Week 8, and Week 12.
Unit: score (0-52 scale points). Change in depressive symptom severity over time assessed by the Hamilton Depression Rating Scale (HAMD-17).
Baseline, Week 4, Week 8, and Week 12.
Incidence of Treatment-Emergent Adverse Events Assessed by the TESS Scale
기간: From randomization through Week 12.
Unit: percent. The incidence of treatment-emergent adverse events assessed by the Treatment Emergent Symptom Scale (TESS).
From randomization through Week 12.
Proportion of Participants Withdrawing Due to Adverse Drug Reactions
기간: From randomization through Week 12.
Unit: percent. The proportion of participants who discontinue the study due to adverse drug reactions.
From randomization through Week 12.
Time to Reach Stable Effective Antidepressant Dose
기간: From randomization through Week 12.
Unit: days. Time required from treatment initiation to reaching a stable and effective antidepressant dose.
From randomization through Week 12.
Concordance Between PGx Recommendations and Prescribed Medication
기간: Baseline (time of first prescription).
Unit: percent. The percentage of prescriptions that are concordant with pharmacogenomic recommendations.
Baseline (time of first prescription).
Frequency of Antidepressant Regimen Adjustments Within 12 Weeks
기간: From randomization through Week 12.
Unit: count. The total number of antidepressant regimen adjustments made during the study period.medication adjustments (including dose changes, drug switches, or addition of adjunctive therapy) made during the 12-week treatment period due to either insufficient therapeutic response or unacceptable adverse effects. This outcome reflects the clinical practicality and stability of the treatment strategy in each arm. The adjustment frequency is compared between the pharmacogenomics-guided therapy group and the conventional treatment group using the Mann-Whitney U test. Descriptive statistics (median, interquartile range) will be reported for each group.
From randomization through Week 12.
Incidence of Clinically Significant Laboratory Abnormalities
기간: Baseline to Week 12.
Unit: percent. Proportion of participants developing clinically significant laboratory abnormalities.
Baseline to Week 12.

기타 결과 측정

결과 측정
측정값 설명
기간
Amplitude of Low-Frequency Fluctuation (ALFF) Levels
기간: Baseline
Unit: z-score. Comparison of ALFF z-scores between MDD patients and healthy controls using ANCOVA.
Baseline
Functional Connectivity Density (FCD)
기간: Baseline
Unit: z-score. Comparison of baseline FCD z-scores between groups.
Baseline
Correlation Between Baseline VMHC and Change in HAMD-17 Score at 12 Weeks
기간: Baseline VMHC with Week 12 HAMD-17 change
Unit: Pearson correlation coefficient (r). Correlation analysis between baseline voxel-mirrored homotopic connectivity (VMHC) and change in HAMD-17 score.
Baseline VMHC with Week 12 HAMD-17 change
Serum C-Reactive Protein (CRP) Concentration
기간: Baseline
Unit: mg/L Description: Case-control t-test/Mann-Whitney; within-patients, Pearson correlation with baseline HAMD-17 and Week-12 % change.
Baseline
Serum Interleukin-6 (IL-6) Concentration
기간: Baseline
Unit: pg/mL
Baseline
Serum Brain-Derived Neurotrophic Factor (BDNF) Concentration
기간: Baseline
Unit: ng/mL Description: Same as #14.
Baseline
Serum Thyroid-Stimulating Hormone (TSH) Concentration
기간: Baseline
Unit: mIU/L Description: Same case-control and correlation analyses.
Baseline
Serum Free Triiodothyronine (FT3) Concentration
기간: Baseline
Unit: pmol/L Description: Same case-control and correlation analyses.
Baseline
Serum Free Thyroxine (FT4) Concentration
기간: Baseline
Unit: pmol/L Description: Same case-control and correlation analyses.
Baseline
Multimodal Integrated Predictive Model Performance for 12-Week Response
기간: Baseline predictors with Week 12 outcome
Unit: Area under ROC curve (AUC), sensitivity (percent), specificity (percent). Performance of the logistic regression model integrating clinical, PGx, VMHC, and blood biomarkers.
Baseline predictors with Week 12 outcome
Genotype-Phenotype Associations with 12-Week Clinical Outcomes
기간: Baseline genotyping; outcomes at Week 12
Unit: Odds ratio (OR). Association of CYP2D6/CYP2C19 metabolizer phenotypes with response, remission, and adverse events.Description: Compare response/remission/AE rates across CYP2D6/CYP2C19 metabolizer phenotypes. Chi-square/Fisher's for categorical; ANOVA/Kruskal-Wallis for continuous % reduction.
Baseline genotyping; outcomes at Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2029년 1월 19일

연구 완료 (추정된)

2029년 1월 19일

연구 등록 날짜

최초 제출

2026년 6월 28일

QC 기준을 충족하는 최초 제출

2026년 7월 29일

처음 게시됨 (실제)

2026년 7월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 31일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 29일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다